Drugs / TABP EIC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03692663 | Dec 2018 → Jun 2023 | prostate carcinoma | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TABP EIC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03692663 ↗ |
| Route | Intravenous | “TABP EIC will be iv administered” NCT03692663 ↗ |